Positive Initial Clinical Data Announced in Ph 1 Clinical Trial of SENTI-202 for the Treatment of R/R Hematologic Malignancies Including AML December 4, 2024
Positive Results from the Ongoing Clinical Trial of BTK Degrader NX-5948 in Patients with R/R Waldenstrom’s Macroglobulinemia Presented October 22, 2024
CRLs submitted to request lifting the clinical holds for zevorcabtagene autoleucel, satricabtagene autoleucel and CT071 October 15, 2024
Positive Interim Ph 1 Results for P-BCMA-ALLO1 with High ORR in Heavily Pretreated RRMM Patients Reported October 8, 2024
FDA Clears IND Application for UB-VV111, a CD19 Directed in situ CAR-T for Heme Malignancies August 6, 2024
OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies July 1, 2024
EMA accepts under Accelerated Assessment of MAA for UM171 Cell Therapy for patients with heme malignancies who lack a readily available suitable donor July 1, 2024
Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Ph 1/2 Clinical Trial of MB-106 Announced June 25, 2024
Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib June 18, 2024
Ph 1 Trial of Menin Inhibitor HMPL-506 Initiated in Patients with Hematological Malignancies in China June 11, 2024
First Patient Dosed in Ph 1 Trial of SENTI-202 for the Treatment of R/R Hematologic Malignancies Including AML May 21, 2024
TC BioPharm Announces Execution of Second Non-Binding Letter of Intent for Acquisition, Targeting Innovative CAR-T Therapies May 14, 2024
SNIPR Biome receives funding from CARB-X to support advancement of CRISPR medicine SNIPR001 into clinical trials in haematological cancer patients April 23, 2024
Edgewood Oncology raises $20 Million in Series A Financing to Advance BTX-A51 in Patients with Hematologic Malignancies and Genetically-Defined Solid Tumors April 2, 2024
Enrollment of 190 Patients to Support Primary Endpoint Analysis in SELECT-MDS-1 Ph 3 Trial completed April 2, 2024
IMBRUVICA® (ibrutinib) Label expanded in the U.S. to Include Oral Suspension Formulation for Adult Patients in its Approved Indications March 12, 2024
Dosing Initiated in Second Cohort of Ovarian Cancer FSHR-targeting CER-T Clinical Trial February 26, 2024
First Patient Dosed in Ph 1a Study with AVC-201 for the Treatment of R/R AML and other CD123 Heme Malignancies February 26, 2024
IND Applications approved by the U.S. FDA and China CDE for the First EpCAM CAR-T Targeted at Advanced Solid Tumors February 26, 2024
